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Anticonvulsant agentsAbstract A new series of 6-iodo-2-phenyl-3-substituted-quinazolin-4(3H)-one (5–12a–b) derivatives
were synthesized, evaluated for their anticonvulsant activity against pentylenetetrazole (PTZ)-
induced seizures and maximal electroshock test and compared with the reference drugs phenobar-
bital sodium and methaqualone. The neurotoxicity was assessed using rotarod test. The molecular
docking was performed for all the synthesized compounds to assess their binding afﬁnities to
GABA-A receptor in order to rationalize their anticonvulsant activities in a qualitative way. The
data obtained from the molecular modeling were correlated with those obtained from the biological
screening. Compounds 9a, 9b, 12a and 7a showed the highest anticonvulsant activities of this series
with relatively low neurotoxicity and low toxicity in the median lethal dose test when compared
with the reference drugs. The obtained results proved that the most active compounds could be a
useful model for future design, adaptation and investigation to construct more active analogs.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Quinazolin-4(3H)-ones and their derivatives constitute an
important class of heterocyclic compounds and are shown to
have potent CNS activities such as anticonvulsant1–6 and CNS
depressant.7 A literature survey revealed that the presence of
an aromatic or aliphatic group at position 2 and a substituted
aromatic ring at position 3 are necessary requirements for the
CNS depression and anticonvulsant activities.4,8 The presence
of the phenyl group at second position of quinazolin-4(3H)-one was more signiﬁcant than methyl and yielded more potent
CNS active agents.4 The sedative-hypnotic (neurotoxicity)
properties of 4(3H)-quinazolinone are well documented.9
2-Methyl-3-O-tolyl 4(3H)-quinazolinone (methaqualone) is an
important landmark in the ﬁeld of synthetic anticonvulsant,
possesses quinazoline core which was responsible for its activ-
ity.10,11 Many quinazoline derivatives were reported as
GABA-A receptor stimulants.2,4 The GABA-A receptor is an
ionotropic receptor and a ligand-gated ion channel. Its endoge-
nous ligand is c-aminobutyric acid (GABA), the major inhibi-
tory neurotransmitter in the central nervous system. Upon
activation, the GABA-A receptor selectively conducts Cl
through its pore, resulting in hyperpolarization of the neuron.
This causes an inhibitory effect on neurotransmission by dimin-
ishing the chance of a successful action potential.2 The active
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several drugs such as muscimol. The protein also contains a
number of different allosteric binding sites which modulate the
activity of the receptor indirectly. These allosteric sites are the
targets of various other drugs, including benzodiazepines, bar-
biturates and ethanol.12 Methaqualone is a positive allosteric
GABA-A receptor modulator. It binds to allosteric sites on
the GABA-A receptor complex and affects it in a positive man-
ner, causing increased efﬁciency of themain site and therefore an
indirect increase in Cl conductance.12 Many quinazolinones
structurally related to compound methaqualone were synthe-
sized and biologically tested for their anticonvulsant activity.
None of those compounds are currently used.11,13 A persistent
problem encountered with these compounds arises from the fact
that, nearly every derivative tested in combined neurotoxicity
and anticonvulsant screenings exhibited neurotoxicity values
(TD50’s) that are less than or only slightly higher than the effec-
tive doses (ED50’s) consequently, the protective index (PI) cor-
responding to (TD50/ED50) is too low.14
In continuation to the efforts done toward the synthesis of
potential molecules as anticonvulsant agents, our aim was to
synthesize new 6-iodo-2-phenyl-3-substituted-quinazolin-
4(3H)-one (5–12) derivatives and evaluate their anticonvulsant
potency. It was of special importance to incorporate some moi-
eties that were reported to potentiate the anticonvulsant activ-
ity such as pyrazoles,15,16 pyrimidones, pyrimidinethiones,17,18
pyridines,19 pyrans20 and to furnish the target compounds.
Moreover, the choice of substituents was based on their rela-
tively high lipophilicity to pass the blood–brain barrier aiming
to have strong anticonvulsant activity.2. Results and discussion
2.1. Rationale and structure-based design
Various reported facts were analyzed before the chemical syn-
thesis of our target compounds. First fact was: modiﬁcations
at second and third positions of methaqualone have led to
the generation of many CNS active agents such as aﬂoqualone,
etaqualone, mebroqualone and mecloqualone (Fig. 1).
Mecloqualone was found to possess a signiﬁcant anticonvul-
sant action 1.5 times more potent than phenytoin against
MES-induced convulsions and ten times more potent than
troxidone against PTZ-induced seizures.14 Second fact was:
presence of the phenyl group at second position of
quinazolin-4(3H)-one was more signiﬁcant than methyl and
yielded more potent CNS active agents as in compounds
(A).4 Third fact explained that: substitution of the quinazoli-
none ring with halogens or an electron rich group at sixth or
eighth positions greatly enhanced the anticonvulsant activity
as in compounds (B) and (C) which have been reported to pos-
sess better activity, longer duration and lower toxicity than
phenytoin.1,21 Fig. 1 represents the structural similarities and
pharmacophoric features of some reported anticonvulsants
quinazolinones and our designed compounds. Based on the
previously mentioned facts, it appeared to us that considerable
promise for discovering new anticonvulsants might be found
through the synthesis of structural analogs of these
compounds.
Fig. 1 shows that structure of the title ﬁnal compounds (6–
12) fulﬁlled all the pharmacophoric structural requirements.These requirements include: the presence of quinazolin-
4(3H)-one moiety as hydrophobic portion, N as electron donor
system, the presence of the carbonyl group as hydrogen bond-
ing site and the phenyl ring at 3-position as hydrophobic
domain substituted with another hydrophobic distal moiety
responsible for controlling the pharmacokinetic properties of
the antiepileptic activity.
The present study was carried out to prepare the target
compounds as hybrid molecules. These molecules formed of
quinazolinone ring system joined with the phenyl ring at 3-
position having different substituents with different electronic
environments to study the SAR of these compounds and the
effect of each substituent on their anticonvulsant activity.
Our target compounds are designed to maintain basic features
of the lead structure methaqualone and replacement of the
methyl group at position 2 of synthesized compounds by the
phenyl group as hydrophobic portion hoping to obtain more
potent anticonvulsant agents. All the target compounds con-
tain iodine. Iodine was selected because it has received consid-
erable attention in organic synthesis due to its high tolerance
to air and moisture, low-cost, nontoxic nature, and ready
availability.1,22 The presence of iodine at sixth position
increases the lipophilicity of the molecules, the hydrophobic
surface of contact, the absorption and the distribution.23
This study was carried out in hope of developing potent,
safe, new and effective anticonvulsant agents with low dose-
related toxicity and without idiosyncratic side effects.
2.2. Molecular docking study
The obtained results indicated that all studied ligands have
similar position and orientation inside the putative binding site
of GABA-A receptor (PDB code 4COF) which reveals a large
space bounded by a membrane-binding domain which serves
as an entry channel for substrate to the active site (Fig. 2).
In addition, the afﬁnity of any small molecule can be consid-
ered as a unique tool in the ﬁeld of drug design. There is a rela-
tionship between the afﬁnity of organic molecules and the free
energy of binding. This relationship can contribute in predic-
tion and interpretation of the activity of the organic com-
pounds toward the speciﬁc target protein.24 The obtained
results of the free energy of binding (DG) explained that most
of these compounds had good binding afﬁnity toward the
receptor and the computed values reﬂected the overall trend
(Table 1). The proposed binding mode of methaqualone
revealed an afﬁnity value of 50.69 kcal/mol and the carbonyl
group formed H-bond with Lysine215 (ANH group) with a
distance of 1.52 A˚ and N1 formed another hydrogen bond
with Isoleucine218 (ANH group) (1.81 A˚). These are key
amino acids acting as a gate for ligand entrance to the
GABA-A (Fig. 3). The quinazolinone moiety occupied the
hydrophobic pocket formed by Glutamine185, Serine187,
Asparagine217 and Glycine219. The phenyl ring at 3-position
was oriented in the hydrophobic cleft formed by Leucine145,
Aspartate146, Glutamate147 and Valine447. The methyl group
at 2-position was oriented in the hydrophobic cleft formed by
Proline144, Arginine216 and Isoleucine218.
The proposed binding mode of compound 9a (afﬁnity value
of 72.29 kcal/mol and 3 H-bonds) is virtually the same as
that of methaqualone (Fig. 4) where the carbonyl group
formed one hydrogen bond with Lysine215 (ANH group) with
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Figure 1 Structural similarities and pharmacophoric features of reported and designed quinazolinones (6–12) as anticonvulsants.
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with Isoleucine218 (ANH group) with a distance of 2.77 A˚.
N4 of the pyrimidinethione side chain formed an extra hydro-
gen bond with the residue Arginine142 (ANH group) (1.65 A˚).
The 6-iodoquinazolinone moiety occupied the hydrophobic
pocket formed by Glutamine185, Serine187, Asparagine217
and Glycine219. The phenyl ring at 3-position was oriented
in the hydrophobic cleft formed by Leucine145,
Aspartate146, Glutamate147 and Valine447. The phenyl group
at 2-position was oriented in the hydrophobic cleft formed by
Tyrosine143, Proline144, Isoleucine218, Tryptophan443 and
Valine447. The 4-chlorophenyl moiety of pyrimidinethione
side chain was oriented in the hydrophobic cleft formed by
Arginine142, Aspartate146 and Glutamate147. These interac-
tions of compound 9a may explain the highest binding free
energy and anticonvulsant activity.Moreover the proposed binding mode of compounds 9b
(afﬁnity value of 71.87 kcal/mol and 3 H-bonds) is virtually
the same as that of 9a (Fig. 5) where the carbonyl group
formed one hydrogen bond with Lys215 (ANH group)
(2.93 A˚) and N1 formed another hydrogen bond with Iso218
(ANH group) (2.84 A˚). N4 of the pyrimidinethione side chain
formed an extra hydrogen bond with the residue Arg142
(ANH group) (1.62 A˚). The 6-iodoquinazolinone moiety occu-
pied the hydrophobic pocket formed by Glu185, Ser187,
Asp217 and Gly219. The phenyl ring at 3-position was oriented
in the hydrophobic cleft formed by Leu145, Asp146, Glu147
and Val447. The phenyl group at 2-position was oriented in
the hydrophobic cleft formed by Tyr143, Pro144, Iso218,
Try443 and Val447. The 4-hydroxyphenyl moiety of pyrim-
idinethione side chain was oriented in the hydrophobic cleft
formed by Arg142, Asp146 and Glu147. These interactions of
Figure 2 Docking and superimposition of compounds 9a, 9b, 12a, and methaqualone in the vicinity of GABA-A receptor (4COF).
Table 1 The calculated DG (free energy of binding) and
binding afﬁnities for the ligands.
Compounds DG (kcal mol1) Compounds DG (kcal mol1)
5a 55.74 9b 71.87
5b 51.82 10a 55.12
5c 62.65 10b 56.60
5d 58.81 10c 59.98
5e 65.76 10d 63.60
6a 66.84 11a 57.02
6b 65.68 11b 53.61
7a 69.68 11c 62.13
7b 67.50 11d 61.04
8a 68.97 12a 71.48
8b 65.48 12b 67.96
9a 72.29 Methaqualone 50.69
Figure 3 Predicted binding mode for methaqualone with GABA
104 M.-K. Ibrahim et al.compound 9b may explain the highest binding free energy and
anticonvulsant activity.
Furthermore the proposed binding mode of compounds 12a
(afﬁnity value of 71.48 kcal/mol and 3 H-bonds) is virtually
the same as that of 9a and 9b (Fig. 6) where N1 formed H-
bond with Iso218 (ANH group) (3.21 A˚). The pyran side chain
was stabilized by formation of 2 H-bonds where its oxygen
atom of formed H-bond with the residue Arg142 (ANH group)
(2.71 A˚) and NH2 group formed another H-bond with the resi-
due Tyrosine446 (O atom) (2.56 A˚). The 6-iodoquinazolinone
moiety occupied the hydrophobic pocket formed by Glu185,
Ser187, Asp217 and Gly219. The phenyl ring at 3-position
was oriented in the hydrophobic cleft formed by Leu145,
Asp146, Glu147 and Val447. The phenyl group at 2-position
was oriented in the hydrophobic cleft formed by Tyr143,
Pro144, Iso218, Try443 and Val447. The 4-chlorophenyl moi-
ety of pyran side chain was oriented in the hydrophobic cleft-A receptor (4COF). H-bonds are indicated by dotted lines.
Figure 4 Predicted binding mode for compound 9a with GABA-A receptor.
Figure 5 Predicted binding mode for compound 9b with GABA-A receptor.
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compound 12a may explain the highest binding free energy
and anticonvulsant activity.
2.3. Chemistry
The sequence of reactions used in the synthesis of the target
compounds is illustrated in Schemes 1–3. A new series of the
title compounds incorporated into diverse N and O hetero-
cyclic moieties were synthesized starting with anthranilic acid
by its reaction with iodine in the presence of aqueous KOH
to give 5-iodoanthranilic acid (1) which treated with benzoyl
chloride to afford N-benzoyl-5-iodoanthranilic acid (2) follow-
ing the reported procedures.25 Reﬂuxing of N-benzoyl-5-
iodoanthranilic acid (2) in acetic anhydride afforded 6-iodo-
2-phenyl-4H-3,1-benzoxazin-4-one (3) which reacted with 4-
aminoacetophenone to give the key intermediate compound,
6-iodo-2-phenyl-3-(4-acetylphenyl)-4(3H)-quinazolinone (4).Claisen–Schmidt condensation of the acetyl derivative (4) with
different aromatic aldehydes afforded the corresponding a,b-
unsaturated ketones (chalcones) (5a–e) (Scheme 1), which
underwent cyclization with hydrazine hydrate in absolute etha-
nol to afford the corresponding pyrazoline derivatives (6a–b),
but when the reaction was carried out in glacial acetic acid,
the N-acetyl pyrazoline derivatives (7a–b) were obtained.
Also, cyclocondensation of the unsaturated ketones (5) by urea
and/or thiourea yielded the corresponding tetrahydropyrimi
din-2-ones (8a–b) and/or tetrahydropyri midin-2-thiones (9a–b)
respectively. Moreover, cyclocondensation of the unsaturated
ketone (5a) by ethyl cyanoacetate afforded 2(1H)-pyridone
(10a) in 65% yield (Scheme 2), which was achieved in good
yield (85%) by one pot reaction. The one pot reaction of (4)
with appropriate aromatic aldehydes and either ethyl cyanoac-
etate or malononitrile in the presence of excess anhydrous
ammonium acetate in n-butanol afforded the corresponding
2(1H)-pyridones (10a–d) or 2(1H)-iminopyridines (11a–d)
Figure 6 Predicted binding mode for compounds 12a with GABA-A receptor.
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106 M.-K. Ibrahim et al.respectively. Upon applying the same procedure, using
malononitrile in the presence of piperidine instead of ammo-
nium acetate, the target 2-aminopyrans (12a–b) were obtained
(Scheme 3).2.4. Anticonvulsant screening
The anticonvulsant activity of the target compounds was eval-
uated against pentylenetetrazole (PTZ)-induced seizures and
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and methaqualone as reference standards.26 The acute neuro-
toxicity was done according to the method described by
Dunham and Miya.27 The MES activity model seems highly
predictive of the ability of those anticonvulsants to protect
against generalized tonic–clonic seizures. The scPTZ model
has been proven to be a good predictor of clinical efﬁcacy
against generalized spike-wave epilepsies which are known as
the absence seizures. Thus, the MES and scPTZ screens have
become the most widely employed seizure models for initial
identiﬁcation of candidate anticonvulsants.28
The initial anticonvulsant evaluation showed that all the
target compounds were active against PTZ-induced seizures.Compounds 8a, 9a, 12a and 12b caused 100% protection in a
dose of 150 mg/kg body weight. Compounds 7a and 9b caused
83.33% protection. Compounds 5e, 6a and 7b caused 66.67%
protection, while compounds 10d and 11c caused 50% protec-
tion at the same dose. Compounds 9a and 9b caused 50% pro-
tection in a dose of 75 mg/kg body weight, compounds 7a, 8a,
12a, 12b and methaqualone caused 50% protection in a dose of
100 mg/kg body weight, while the remaining compounds
showed 50% protection at higher doses (Table 2).
The data obtained from biological screening (Table 2)
revealed that; most of the tested compounds showed good
anticonvulsant activities. The tested compounds exhibited rel-
ative anticonvulsant potencies ranging from 0.42 to 0.20 of
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Scheme 3 Synthetic route for the preparation of the target compounds 10–12.
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qualone. It was observed that all the screened compounds
showed lower activities than the reference standard phenobar-
bital (Fig. 7) and showed higher activities than methaqualone
(Fig. 8).
For the MES test (100 mg/kg body weight), compound 9a
showed 83.33% protection, compounds 7a, 9b, 12a, 12b
and methaqualone showed 66.67% protection, compounds
7b, 8a presented 50.00% protection, compound 6a caused
33.33% protection, while the other compounds 5e, 10d and
11c exhibited 16.67% protection. The results are explained in
Table 2.
From the result of preliminary screening, the most active
compounds 7a, 9a, 9b and 12a were subjected to further inves-
tigations in mice i.p. at different doses for quantiﬁcation of
their anticonvulsant activity and neurotoxicity which indicated
by median toxic dose producing minimal neurological toxicity
in 50% of mice (TD50). As demonstrated in Table 3, the
selected compounds 7a, 9a, 9b, and 12a exhibited anticonvul-
sant activity against PTZ-induced seizure with (ED50) values
of 100, 75, 75 and 100 mg/kg, respectively. Methaqualone used
as the reference drug produced (ED50) values of 200 mg/kg.
The (ED50) values of the selected compounds were found to
be smaller than that of the reference anticonvulsant drug.
The protective index (PI) = (TD50/ED50) is deﬁned to be
an index representing the margin of safety and tolerability
between anticonvulsant doses and doses of anticonvulsant
drugs exerting acute adverse effects like sedation, motor coor-
dination impairment, ataxia, or any other neurotoxicmanifestations.29 The most potent compounds 7a, 9a, 9b and
12a had (TD50) values of 225, 250, 200 and 225 mg/kg, respec-
tively. These values revealed that these agents exerted low neu-
rological disorders. From the results of ED50 and TD50,
compounds 7a, 9a, 9b and 12a had (PI) values of 2.25, 3.33,
2.67 and 2.25, respectively, which means that, the most active
compounds 9a, 9b, 12a and 7a had higher (PI) values than that
of the reference drug methaqualone as shown in Table 3. The
present results are implying high safety margin of synthesized
compounds when compared with the reference drug. The ther-
apeutic index (TI) = (LD50/ED50) is a comparison of the
amount of a therapeutic agent that causes the therapeutic
effect to the amount that causes death in mice.14
Compounds 7a, 9a, 9b and 12a had (LD50) values of 325,
400, 350 and 375 mg/kg with (TI) values of 3.25, 5.33, 4.67
and 3.75, respectively. It is worthwhile to note that (TI) values
of the most potent compounds 9a, 9b, 12a and 7a were found to
be higher than that of the reference anticonvulsant drug as
shown in Table 3.
Results of the anticonvulsant screening methods in the pre-
sent study showed that some new quinazolinones were effective
in controlling the seizures induced by PTZ and MES. From the
MES test, one can suggest that the anti-seizure effects of agents
or drugs that suppress tonic–clonic seizures through raising
seizure’s threshold and/or possessing the ability to prevent
the spread of seizure discharge throughout neuronal tissues.27
Concerning their partial effectiveness, our newly synthesized
compounds can control the seizures induced by PTZ and
MES indicating that these compounds exhibited a broad
Table 2 Anticonvulsant activity of the selected compounds.
Test comp. Dose
(mg/kg)
PTZ-
protection (%)
ED50
(mg/kg)
ED50
(mmol/kg)
MES-
protection (%)
Relative potency to
phenob.
Relative potency to
methaq.
C
log P
5e 150 66.67 125 0.22 16.67 0.22 1.82 –
100 33.33
50 16.67
6a 150 66.67 125 0.22 33.33 0.22 1.82 6.881
100 33.33
50 16.67
7a 150 83.33 100 0.16 66.67 0.31 2.50 7.165
100 50.00
50 33.33
7b 150 66.67 125 0.20 50.00 0.25 2.00 6.651
100 33.33
50 16.67
8a 150 100.00 100 0.16 50.00 0.31 2.50 6.547
100 50.00
50 33.33
9a 150 .00100 75 0.11 83.33 0.42 3.45 7.804
100 66.67
50 33.33
9b 150 83.33 75 0.12 66.67 0.41 3. 33 6.647
100 66.67
50 33.33
10d 150 50.00 150 0.23 16.67 0.21 1.74 7.695
100 33.33
50 16.67
11c 150 50.00 150 0.24 16.67 0.20 1.67 5.667
100 33.33
50 16.67
12a 150 100.00 100 0.15 66.67 0.33 2.67 7.679
100 50.00
50 33.33
12b 150 100.00 100 0.16 66.67 0.31 2.50 6.522
100 50.00
50 33.33
Methaqualone 150 100.00 100 0.40 66.67 0.12 1.00 3.026
100 50.00
50 33.33
Phenobarbital 25 100 12.5 0.049 – 1.00 – –
12.5 50
6.25 16.67
Anticonvulsant evaluation of novel 6-iodo-2-phenyl-3-substituted-quinazolin-4(3H)-ones 109spectrum of anticonvulsant activities in animal models of par-
tial and generalized epilepsy.
Structure–activity correlation based on the obtained results
indicated that, modiﬁcations of methaqualone at 2-position by
substitution of the methyl group with phenyl, incorporation of
iodo substituent at 6-position, and incorporation of the phenyl
ring at 3-position having different substituents with different
electronic environments led to a signiﬁcant improvement of
anticonvulsant activity. Different substitutions on the 3-
position from the 4(3H)-quinazolinone ring exerted varied
anticonvulsant activity. The lipophilicity and electronic nature
of the substituent group attached to the quinazoline ring led to
a signiﬁcant variation in the anticonvulsant activity.
From the structure of the newly synthesized compounds
and data shown in Table 2, we concluded that: pyrim-
idinethione, tetrahydropyrimidin-2-one and N-acetyl pyrazo-
line moieties exhibited the highest anticonvulsant activities.
Among these compounds, the presence of substituent with
higher lipophilicity showed higher activity than others withlower lipophilicity. The presence of electron deﬁcient sub-
stituent (4-Cl) gave higher activity than the electron rich group
(OH). The 4-Cl derivative showed higher activity than the 4-F
one. In addition incorporation of pyran and pyrazoline moi-
eties showed intermediate activities while, 2(1H)-pyridone
and/or 2(1H)-iminopyridines moieties had lower activities.
3. C logP correlation
As a trial for interpretation of the correlation between chemi-
cal structure of compounds 6a, 7a, 7b, 8a, 9a, 9b, 10d, 11c, 12a
and 12b and their biological activity, an attempted correlation
of anticonvulsant activity with C log P data was calculated for
the measurement of the lipophilicity factor which could be
attributed in their anticonvulsant activity. For antiepileptic
agents to be effective, they have to cross the blood brain bar-
rier (BBB).30 Crossing the brain is therefore a crucial step in
developing effective drug therapies for treatment of neurolog-
ical disorders. Lipophilic substances are able to permeate into
Figure 7 Relative potencies of the tested compounds and methaqualone in comparison with Phenobarbital.
Figure 8 Relative potencies of the tested compounds in comparison with methaqualone.
Table 3 ED50, TD50, LD50, therapeutic index (TI) and protective index (PI) for the most active compounds 7a, 9a, 9b and 12a
compared to the reference drug methaqualone.
Compounds ED50 (mg/kg) TD50 (mg/kg) LD50 (mg/kg) Therapeutic index (TI) Protective index (PI)
7a 100 225 325 3.25 2.25
9a 75 250 400 5.33 3.33
9b 75 200 350 4.67 2.67
12a 100 225 375 3.75 2.25
Methaqualone 200 400 500 2.50 2.00
ED50 = median effective dose providing anticonvulsant protection in 50% of mice against pentylenetetrazole (PTZ) induced seizures.
TD50 = median toxic dose producing minimal neurological toxicity in 50% of mice.
LD50 = median lethal dose that causes 50% mortality in mice.
Therapeutic index = LD50/ED50.
Protective index = TD50/ED50.
110 M.-K. Ibrahim et al.the brain interstitium in a relatively easy way.1 Determination
of brain–blood partitioning in vitro is difﬁcult, time-
consuming, expensive, not always available and not suitableto screen a large collection of new chemicals. Therefore, an
alternative method was used based on computerized models.
So, the C log P values were calculated for some compounds
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pared. It is postulated that a C log P value of at least 2.0 is
required by a speciﬁc compound to cross the BBB.31 The C
log P data for all selected anticonvulsant compounds are
explained in Table 2 ranging from 5.667 to 7.804. All the com-
pounds were found to have C log P values above 2 (which
required for effective penetration in the brain) and higher than
that of methaqualone. It is worthwhile to note that the C log P
values for compounds 9a, 12a and 7a which had higher potency
were higher than those of other compounds which might
explain the signiﬁcant variation in their biological activity in
correlation with their lipophilicity. In spite of compound 9b
having higher anticonvulsant potency than compounds 12a
and 7a, it had lower C log P value and had no correlation with
the lipophilicity factor while compounds 10d, 7b and 6a had
higher C log P values (7.695, 6.651 and 6.881, respectively)
and had no correlation with the lipophilicity factor.
Interestingly, the values of C log P for the selected potent com-
pounds agree with their potency levels, compound 9a which
had the highest activity, also had the highest C log P value
(7.804), while compound 12b which had the medium activity,
had medium C log P value (6.522) and compound 11c had
the lowest C log P value as its activity (5.667). In general, it
was found that compounds having more C log P values had
higher potency as anticonvulsant agents.
4. Conclusion
New derivatives of 4(3H)-quinazolinones were synthesized and
evaluated for their anticonvulsant activity in mice. The results
of this study demonstrated that some 6-iodo-2-phenyl-
quinazolin-4(3H)-one derivatives attached to various hetero-
cyclic ring systems such as: pyrazoline, pyrimidin-2-one,
pyrimidin-2-thione, 2-oxo(imino)pyridine and pyran at 3rd
position exhibited good anticonvulsant activity. The molecular
docking was performed for all the synthesized compounds to
assess their binding afﬁnities to GABA-A receptor in order
to rationalize their anticonvulsant activities in a qualitative
way. The data obtained from the molecular modeling were
correlated with those obtained from the biological screening.
Compounds 9a, 9b, 12a and 7a showed the highest anticonvul-
sant activities of this series with relatively low neurotoxicity
and low toxicity in the median lethal dose test when compared
with the reference drugs. The obtained results showed that
compounds 9a, 9b, 12a and 7a could be useful as a template
for future design, optimization, and investigation to produce
more active analogs.
5. Experimental
5.1. Chemistry
All melting points were carried out by the open capillary
method on a Gallen kamp Melting point apparatus at faculty
of pharmacy Al-Azhar University and were uncorrected. The
infrared spectra were recorded on a pye Unicam SP 1000 IR
spectrophotometer at Pharmaceutical Analytical Unit,
Faculty of Pharmacy, Al-Azhar University using the potas-
sium bromide disk technique. Proton magnetic resonance 1H
NMR spectra were recorded on a jeol 400 MHz-NMR spec-
trometer at Microanalytical Center, Cairo University andMicroanalytical Center, Asuit University. TMS was used as
internal standard and chemical shifts were measured in d scale
(ppm). The mass spectra were recorded on Varian MAT 311-A
(70 e.v.) at Regional Center for Mycology and Biotechnology,
Al-Azhar University and Direct Inlet unit (DI-50) of
SHIMADZU GC/MS–QP5050A at Microanalytical Center,
Cairo University. Elemental analyses (C, H, N) were per-
formed on a CHN analyzer at Regional Center for
Mycology and Biotechnology, Al-Azhar University. All com-
pounds were within ±0.4 of the theoretical values. The reac-
tions were monitored by thin-layer chromatography (TLC)
using TLC sheets precoated with UV ﬂuorescent silica gel
Merck 60 F254 plates and were visualized using UV lamp
and different solvents as mobile phases.
5-Iodoanthranilic acid (1), N-benzoyl-5-iodoanthranilic
acid (2), 6-iodo-2-phenyl-4H-3,1-benzoxazin-4-one (3) and
3-(4-acetylphenyl)-6-iodo-2-phenylquinazolin-4(3H)-one (4) were
obtained according to the reported procedures.
5.1.1. 3-(4-Acetylphenyl)-6-iodo-2-phenylquinazolin-4(3H)-one
(4)
A mixture of compound (3) (3.49 g, 0.01 mol) and 4-
aminoacetophenone (1.35 g, 0.01 mol) in acetic acid glacial
(20 ml) was reﬂuxed for 4 h. After cooling, the reaction mix-
ture was poured carefully portion wise onto ice-water
(300 ml) while stirring and the separated solid was ﬁltered,
dried and crystallized from ethanol twice to give the corre-
sponding acetyl derivative (4).
Yield, 82%; m.p.: 230–2 C. Analysis for C22H15IN2O2 (m.
w. 466); Calcd.: C, 56.67; H, 3.24; N, 6.01. Found: C, 56.68; H,
3.27; N, 6.12. IR (KBr, cm1): 3075 (CH aromatic), 2970 (CH
aliphatic), 1760 (C‚O of acetyl), 1690 (C‚O of quinazoli-
none). 1H NMR (DMSO-d6, ppm): 2.5 (s, 3H, CH3), 7.49–
8.09 (m, 12H, aromatic protons). MS (m/z): 467 (M+1,
4.58%), 466 (M+, 16.36%), 465 (11.39%), 350 (13.66%),
105 (35.70%), 77 (100%).5.1.2. 6-Iodo-2-phenyl-3-(4-(3-(substituted)acryloyl)phenyl)
quinazolin-4(3H)-one (chalcones) (5a–e)
General method:
To a mixture of the ketone (4) (0.93 g, 0.002 mol) and the
appropriate aromatic aldehyde (0.002 mol) in ethyl alcohol
(10 ml), 5% NaOH in ethyl alcohol (10 ml) was added drop-
wise within 15 min. The reaction mixture was reﬂuxed for
3 h, then cooled and the formed precipitate was ﬁltered, air
dried and then recrystallized from ethanol to give the corre-
sponding chalcones (5a–e) respectively.5.1.2.1. 6-Iodo-2-phenyl-3-(4-(3-phenylacryloyl)phenyl)quina-
zolin-4(3H)-one (5a). Yield, 94%; m.p.: 175–7 C. Analysis
for C29H19IN2O2 (m. w. 554); Calcd.: C, 62.83; H, 3.45; N,
5.05. Found: C, 62.88; H, 3.48; N, 5.19. IR (KBr, cm1):
3072 (CH aromatic), 1730 (C‚O of a,b-unsaturated ketone),
1668 (C‚O of quinazolinone). 1H NMR (DMSO-d6, ppm):
7.52–8.19 (m, 19H, CH‚CH overlapped with the aromatic
protons). MS (m/z): 553 (M1, 0.62%), 350 (2.76%), 105
(35.33%), 77 (59.65%), 50 (100%).
5.1.2.2. 3-(4-(3-(4-Chlorophenyl)acryloyl)phenyl)-6-iodo-2-
phenylquinazolin-4(3H)-one (5b). Yield, 80%; m.p.: 180–
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59.15; H, 3.08; N, 4.76. Found: C, 59.18; H, 3.06; N, 4.83.
IR (KBr, cm1): 3083 (CH aromatic), 1731 (C‚O of a,b-
unsaturated ketone), 1681 (C‚O of quinazolinone). 1H
NMR (DMSO-d6, ppm): 7.51–8.51 (m, 18H, CH‚CH over-
lapped with the aromatic protons). MS (m/z): 591 (M+2,
5.1%), 589 (M+, 10.27%), 350 (100%), 120 (52.74%), 77
(68.23%), 50 (54.90%).
5.1.2.3. 3-(4-(3-(4-Fluorophenyl)acryloyl)phenyl)-6-iodo-2-
phenylquinazolin-4(3H)-one (5c). Yield, 87%; m.p.: 173–
5 C. Analysis for C29H18FIN2O2 (m. w. 572); Calcd.: C,
60.85; H, 3.17; N, 4.89. Found: C, 60.83; H, 3.22; N, 5.02.
IR (KBr, cm1): 3061 (CH aromatic), 1725 (C‚O of a,b-
unsaturated ketone), 1654 (C‚O of quinazolinone). 1H
NMR (DMSO-d6, ppm): 7.53–8.52 (m, 18H, CH‚CH over-
lapped with the aromatic protons). MS (m/z): 571 (M1,
1.29%), 466 (1.33%), 350 (40.30%), 105 (73.80%), 77
(100%), 50 (82.74%).
5.1.2.4. 3-(4-(3-(4-Hydroxyphenyl)acryloyl)phenyl)-6-iodo-2-
phenylquinazolin-4(3H)-one (5d). Yield, 83%; m.p.: 170–2 C.
Analysis for C29H19IN2O3 (m. w. 570); Calcd.: C, 61.07; H,
3.36; N, 4.91. Found: C, 61.13; H, 3.34; N, 4.98. IR (KBr,
cm1): 3428 (OH), 3067 (CH aromatic), 1730 (C‚O of a,b-
unsaturated ketone), 1653 (C‚O of quinazolinone). 1H
NMR (DMSO-d6, ppm): 7.51–8.50 (m, 18H, CH‚CH over-
lapped with the aromatic protons), 15.69 (s, 1H, OH) (D2O
exchangeable).
5.1.2.5. 6-Iodo-2-phenyl-3-(4-(3-(4-methylphenyl)acryloyl)
phenyl)quinazolin-4(3H)-one (5e). Yield, 85%; m.p.: 185–
7 C. Analysis for C30H21IN2O2 (m. w. 568); Calcd.: C,
63.39; H, 3.72; N, 4.93. Found: C, 63.36; H, 3.77; N, 5.04.
IR (KBr, cm1): 3070 (CH aromatic), 1724 (C‚O of a,b-
unsaturated ketone), 1655 (C‚O of quinazolinone). 1H
NMR (DMSO-d6, ppm): 2.51 (s, 3H, CH3), 7.21–8.48 (m,
18H, CH‚CH overlapped with the aromatic protons). MS
(m/z): 567 (M1, 1.50%), 350 (38.20%), 105 (62.98%), 77
(100%), 50 (95.08%).
5.1.3. 6-Iodo-2-phenyl-3-(4-(5-substituted-4,5-dihydro-1H-
pyrazol-3-yl)phenyl)quinazolin-4(3H)-one (6a–b)
General method:
A mixture of the appropriate chalcone (5) (0.005 mol) and
hydrazine hydrate (2.5 ml, 0.005 mol, 98%) in absolute etha-
nol (25 ml) was reﬂuxed for 10 h. After cooling, the separated
precipitate was ﬁltered, air dried and recrystallized from etha-
nol to afford the corresponding pyrazoline derivatives (6a–b)
respectively.
5.1.3.1. 6-Iodo-2-phenyl-3-(4-(5-phenyl-4,5-dihydro-1H-pyra-
zol-3-yl)phenyl)quinazolin-4(3H)-one (6a). Yield, 72%; m.p.:
217–9 C. Analysis for C29H21IN4O (m. w. 568); Calcd.: C,
61.28; H, 3.72; N, 9.86. Found: C, 61.26; H, 3.78; N, 9.88.
IR (KBr, cm1): 3200 (NH), 3085 (CH aromatic), disappear-
ance of absorption band at 1730 (C‚O of chalcone), 1637
(C‚O of quinazolinone). 1H NMR (DMSO-d6, ppm): 1.06
(dd, 2H, CH2 of pyrazoline), 3.45 (t, 1H, CH of pyrazoline),
7.53–8.50 (m, 17H, aromatic protons), 15.61 (s, 1H, NH).5.1.3.2. 6-Iodo-3-(4-(5-(4-chlorophenyl)-4,5-dihydro-1H-pyra-
zol-3-yl)phenyl)-2-phenyl-quinazolin-4(3H)-one (6b). Yield,
79%; m.p.: 231–3 C. Analysis for C29H20ClIN4O (m. w.
603); Calcd.: C, 57.78; H, 3.34; N, 9.29. Found: C, 57.58; H,
3.05; N, 9.06. IR (KBr, cm1): 3250 (NH), disappearance of
absorption band of (C‚O of chalcone), 1667 (C‚O of quina-
zolinone). 1H NMR (DMSO-d6, ppm): 1.06 (dd, 2H, CH2 of
pyrazoline), 3.47 (t, 1H, CH of pyrazoline), 7.27–8.51 (m,
16H, aromatic protons), 15.50 (s, 1H, NH).
5.1.4. 3-(4-(1-Acetyl-5-substituted-4,5-dihydro-1H-pyrazol-3-
yl)phenyl)-6-iodo-2-phenyl-quinazolin-4(3H)-one (7a–b)
General method:
A mixture of the appropriate chalcone (5) (0.005 mol) and
hydrazine hydrate (2.5 ml, 0.005 mol, 98%) in the presence
of acetic acid glacial (10 ml) was reﬂuxed for 6 h. After cool-
ing, the separated precipitate was ﬁltered, air dried and recrys-
tallized from ethanol to afford the corresponding N-
acetylpyrazoline derivatives (7a–b) respectively.
5.1.4.1. 3-(4-(1-Acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-
pyrazol-3-yl)phenyl)-6-iodo-2-phenylquinazolin-4(3H)-one
(7a). Yield, 76%; m.p.: 162–4 C. Analysis for C31H22ClIN4O2
(m. w. 644); Calcd.: C, 57.74; H, 3.44; N, 8.69. Found: C,
57.79; H, 3.46; N, 8.82. IR (KBr, cm1): 3039 (CH aromatic),
1688 (C‚O of acetyl), 1643 (C‚O of quinazolinone). 1H
NMR (DMSO-d6, ppm): 1.24 (dd, 2H, CH2 of pyrazoline),
2.54 (s, 3H, CH3), 3.20 (t, 1H, CH of pyrazoline), 7.21–8.48
(m, 16H, aromatic protons). MS (m/z): 642 (M2, 16.02%),
350 (17.35%), 105 (40.75%), 77 (100%), 69 (70.68%), 51
(73.82%).
5.1.4.2. 3-(4-(1-Acetyl-5-(4-ﬂourophenyl)-4,5-dihydro-1H-
pyrazol-3-yl)phenyl)-6-iodo-2-phenylquinazolin-4(3H)-one
(7b). Yield, 70%; m.p.: 156–8 C. Analysis for C31H22FIN4O2
(m. w. 628); Calcd.: C, 59.25; H, 3.53; N, 8.92. Found: C,
59.66; H, 3.37; N, 9.03. IR (KBr, cm1): 3045 (CH aromatic),
1693 (C‚O of acetyl), 1650 (C‚O of quinazolinone). 1H
NMR (DMSO-d6, ppm): 1.08 (dd, 2H, CH2 of pyrazoline),
2.51 (s, 3H, CH3), 3.41 (t, 1H, CH of pyrazoline), 7.50–8.50
(m, 16H, aromatic protons). MS (m/z): 628 (M+, 0.05%),
350 (0.14%), 105 (36.89%), 76 (100%), 62 (33.01%), 50
(85.98%).
5.1.5. 6-Iodo-3-(4-(2-oxo-6-substituted-1,2,5,6-
tetrahydropyrimidin-4-yl)phenyl)-2-phenyl-quinazolin-4(3H)-
one (8a–b)
General method:
A mixture of the appropriate chalcone (5) (0.005 mol) and
urea (0.5 g, 0.005 mol) in ethanol (20 ml) and conc. HCl
(5 ml) was reﬂuxed for 7 h. The reaction mixture was concen-
trated to half of its volume, cooled and neutralized with
NH4OH solution. The precipitated solid was ﬁltered, washed
with water, air dried and recrystallized from ethanol to give
the corresponding compounds (8a–b) respectively.
5.1.5.1. 3-(4-(6-(4-Chlorophenyl)-2-oxo-1,2,5,6-tetrahydropy-
rimidin-4-yl)phenyl)-6-iodo-2-phenylquinazolin-4(3H)-one
(8a). Yield, 78%; m.p.: 145–7 C. Analysis for C30H20ClIN4O2
(m. w. 630); Calcd.: C, 57.12; H, 3.20; N, 8.88. Found: C,
57.36; H, 2.94; N, 8.97. IR (KBr, cm1): 3105 (NH), 3045
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amidic). 1H NMR (DMSO-d6, ppm): 0.88 (dd, 2H, CH2 of
pyrimidinone), 1.88 (t, 1H, CH of pyrimidinone), 7.07–8.47
(m, 16H, aromatic protons), 10.80 (s, 1H, NH). MS (m/z):
629 (M1, 3.41%), 628 (M2, 0.53%), 350 (1.59%), 105
(17.18%), 77 (74.76%), 68 (5.94%), 50 (100%).
5.1.5.2. 3-(4-(6-(4-Flourophenyl)-2-oxo-1,2,5,6-tetrahydropy-
rimidin-4-yl)phenyl)-6-iodo-2-phenylquinazolin-4(3H)-one (8b).
Yield, 72%; m.p.: 140–2 C. Analysis for C30H20FIN4O2 (m. w.
614); Calcd.: C, 58.65; H, 3.28; N, 9.12. Found: C, 58.73; H,
3.14; N, 8.87. IR (KBr, cm1): 3110 (NH), 3032 (CH aromatic),
1690 (C‚O of quinazolinone), 1650 (C‚O amidic). 1H NMR
(DMSO-d6, ppm): 0.85 (dd, 2H, CH2 of pyrimidinone), 1.88 (t,
1H, CH of pyrimidinone), 7.07–8.48 (m, 16H, aromatic protons),
10.75 (s, 1H, NH). MS (m/z): 614 (M+, 0.05%), 350 (3.16%), 135
(100%), 105 (35.15%), 76 (15.61%), 68 (3.45%), 56 (7.06%).
5.1.6. 6-Iodo-2-phenyl-3-(4-(6-substituted-2-thioxo-1,2,5,6-tetrahy-
dropyrimidin-4-yl)phenyl)-quinazolin-4(3H)-one (9a–b)
General method:
A mixture of the appropriate chalcone (5) (0.005 mol) and
thiourea (0.38 g, 0.005 mol), in the presence of 0.5 g of
NaOH was reﬂuxed in ethanol (25 ml) for 6 h, then concen-
trated under vacuum and neutralized with diluted HCl. The
precipitated material was ﬁltered, washed with water, dried
and recrystallized from ethanol to give the corresponding com-
pounds (9a–b) respectively.
5.1.6.1. 3-(4-(6-(4-Chlorophenyl)-2-thioxo-1,2,5,6-tetrahy-
dropyrimidin-4-yl)phenyl)-6-iodo-2-phenylquinazolin-4(3H)-
one (9a). Yield, 71%; m.p.: 221–3 C. Analysis for
C30H20ClIN4OS (m. w. 646); Calcd.: C, 55.70; H, 3.12; N,
8.66. Found: C, 55.89; H, 2.86; N, 8.77. IR (KBr, cm1):
3293 (NH), 3045 (CH aromatic), 1656 (C‚O of quinazoli-
none), 1593 (C‚N), 1233 (C‚S). 1H NMR (DMSO-d6,
ppm): 1.05 (dd, 2H, CH2 of pyrimidinethione), 1.60 (t, 1H,
CH of pyrimidinethione), 7.50–8.48 (m, 16H, aromatic pro-
tons), 8.50 (s, 1H, NH).5.1.6.2. 3-(4-(6-(4-Hydroxyphenyl)-2-thioxo-1,2,5,6-tetrahy-
dropyrimidin-4-yl)phenyl)-6-iodo-2-phenylquinazolin-4(3H)-
one (9b). Yield, 76%; m.p.: 217–9 C. Analysis for
C30H21IN4O2 (m. w. 628); Calcd.: C, 57.33; H, 3.37; N, 8.91.
Found: C, 57.58; H, 3.09; N, 8.99. IR (KBr, cm1): 3464
(OH), 3290 (NH), 3059 (C-H aromatic), 1652 (C‚O of quina-
zolinone), 1593 (C‚N), 1234 (C‚S). MS (m/z): 628 (M+,
0.53%), 615 (53%), 350 (0.26%), 105 (16.21%), 76 (32.25%),
68 (46.42%), 56 (100%).5.1.7. 6-(4-(6-Iodo-4-oxo-2-phenylquinazolin-3(4H)-yl)phenyl)-
2-oxo-4-substituted-1,2-dihydropyridine-3-carbonitrile (10a–d)
General method:
A mixture of ketone (4) (0.93 g, 0.002 mol), ethyl cyanoac-
etate (0.23 ml, 0.002 mol), anhydrous ammonium acetate
(1.24 g, 0.016 mol) and the appropriate aldehyde (0.002 mol)
in 10 ml of n-butanol was reﬂuxed for 6 h. The reaction mix-
ture was concentrated to half of its volume under reduced pres-
sure. After cooling, the formed precipitate was ﬁltered, airdried and crystallized from ethanol to afford the correspond-
ing compounds (10a–d) respectively.
5.1.7.1. 6-(4-(6-Iodo-4-oxo-2-phenylquinazolin-3(4H)-yl)phe-
nyl)-2-oxo-4-phenyl-1,2-dihydro-pyridine-3-carbonitrile (10a).
Yield, 85%; m.p.: 315–7 C. Analysis for C32H19IN4O2 (m.
w. 618); Calcd.: C, 62.15; H, 3.10; N, 9.06. Found: C, 62.18;
H, 3.15; N, 9.10. IR (KBr, cm1): 3339 (OH enolic of pyri-
done), 3067 (CH aromatic), 2230 (CN), 1673 (C‚O quinazoli-
none). 1H NMR (DMSO-d6, d, ppm): 7.53–8.20 (m, 18H,
aromatic protons including 1 H of pyridone), 10.83 (s, 1H,
NH) (D2O exchangeable), 11.31 (s, 1H, OH of resonance)
(D2O exchangeable). MS (m/z): 619 (M
+1, 4.67%), 351
(5.28%), 105 (41.14%), 77 (36.52%), 51 (100%).
5.1.7.2. 4-(4-Chlorophenyl)-6-(4-(6-iodo-4-oxo-2-phenylquina-
zolin-3(4H)-yl)phenyl)-2-oxo-1,2-dihydropyridine-3-carboni-
trile (10b). Yield, 70%; m.p.: 340–2 C. Analysis for
C32H18ClIN4O2 (m. w. 653); Calcd.: C, 58.87; H, 2.78; N,
8.58. Found: C, 58.88; H, 2.75; N, 8.67. IR (KBr, cm1):
3345 (OH enolic of pyridone), 3067 (CH aromatic), 2226
(CN), 1675 (C‚O quinazolinone). 1H NMR (DMSO-d6, d,
ppm): 7.53–8.19 (m, 17H, aromatic protons including 1 H of
pyridone), 10.82 (s, 1H, NH) (D2O exchangeable), 11.31 (s,
1H, OH of resonance) (D2O exchangeable). MS (m/z): 653
(M+, 0.28%), 350 (49.65%), 135 (73.03%), 105 (84.72%), 77
(100%), 50 (39.90%).
5.1.7.3. 4-(4-Hydroxyphenyl)-6-(4-(6-iodo-4-oxo-2-phenylquina
zolin-3(4H)-yl)phenyl)-2-oxo-1,2-dihydropyridine-3-carboni-
trile (10c). Yield, 83%; m.p.: 300–2 C. Analysis for
C32H19IN4O3 (m. w. 634); Calcd.: C, 60.58; H, 3.02; N, 8.83.
Found: C, 60.61; H, 3.08; N, 8.98. IR (KBr, cm1): 3631,
3339 (2 OH), 3065 (CH aromatic), 2216 (CN), 1673 (C‚O
quinazolinone). MS (m/z): 634 (M+, 0.01%), 351 (77.67%),
135 (75.16%), 76 (100%), 50 (76.16%).
5.1.7.4. 6-(4-(6-Iodo-4-oxo-2-phenylquinazolin-3(4H)-yl)phe-
nyl)-4-(4-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboni-
trile (10d). Yield, 81%; m.p.: 317–9 C. Analysis for
C33H21IN4O2 (m. w. 632); Calcd.: C, 62.67; H, 3.35; N, 8.86.
Found: C, 62.18; H, 3.15; N, 9.10. IR (KBr, cm1): 3337
(OH enolic of pyridone), 3060 (CH aromatic), 2220 (CN),
1676 (C‚O quinazolinone). 1H NMR (DMSO-d6, d, ppm):
2.55 (s, 3H, CH3), 7.56–8.19 (m, 17H, aromatic protons includ-
ing 1 H of pyridone), 10.83 (s, 1H, NH), 11.31 (s, 1H, OH of
resonance). MS (m/z): 634 (M+2, 1.68%), 351 (6.01%), 105
(85.35%), 77 (100%), 50 (76.65%).
5.1.8. 2-Imino-6-(4-(6-iodo-4-oxo-2-phenylquinazolin-3(4H)-yl)
phenyl)-4-substituted-1,2-dihydropyridine-3-carbonitrile (11a–d)
General method:
A mixture of ketone (4) (0.93 g, 0.002 mol), malononitrile
(0.12 ml, 0.002 mol), anhydrous ammonium acetate (1.24 g,
0.016 mol) and the appropriate aldehyde (0.002 mol) in 10 ml
of n-butanol was reﬂuxed for 5 h. The reaction mixture was
concentrated to half of its volume under reduced pressure.
After cooling, the formed precipitate was ﬁltered, air dried
and crystallized from ethanol to afford the corresponding com-
pounds (11a–d) respectively.
114 M.-K. Ibrahim et al.5.1.8.1. 2-Imino-6-(4-(6-iodo-4-oxo-2-phenylquinazolin-3(4H)-
yl)phenyl)-4-phenyl-1,2-dihydropyridine-3-carbonitrile (11a).
Yield, 75%; m.p.: 305–7 C. Analysis for C32H20IN5O (m.
w. 617); Calcd.: C, 62.25; H, 3.26; N, 11.34. Found: C,
62.30; H, 3.28; N, 11.42. IR (KBr, cm1): 3323 (2NH over-
lapped), 3070 (CH aromatic), 2222 (CN), 1687 (C‚O quina-
zolinone). 1H NMR (DMSO-d6, d, ppm): 7.53–8.19 (m, 18H,
aromatic protons including 1 H of pyridine), 10.82 (s, 1H,
HN), 11.30 (s, 1H, NH‚C). MS (m/z): 617 (M+, 0.9%),
351 (16.16%), 105 (100%), 77 (84.10%), 51 (27.10%).
5.1.8.2. 4-(4-Chlorophenyl)-2-imino-6-(4-(6-iodo-4-oxo-2-phenyl
quinazolin-3(4H)-yl)phenyl)-1,2-dihydropyridine-3-carbonitrile
(11b). Yield, 85%; m.p.: 290–2 C. Analysis for
C32H19ClIN5O (m. w. 652); Calcd.: C, 58.96; H, 2.94; N,
10.74. Found: C, 58.94; H, 2.95; N, 10.81. IR (KBr, cm1):
3330, 3202 (2NH), 3043 (CH aromatic), 2203 (CN), 1663
(C‚O quinazolinone). MS (m/z): 652 (M+, 2.12%), 350
(28.18%), 105 (59.43%), 77 (100%), 51 (57.03%).
5.1.8.3. 4-(4-Hydroxyphenyl)-2-imino-6-(4-(6-iodo-4-oxo-2-phenyl
quinazolin-3(4H)-yl)-phenyl)-1,2-dihydropyridine-3-carboni-
trile (11c). Yield, 70%; m.p.: 345–7 C. Analysis for
C32H20IN5O2 (m. w. 633); Calcd.: C, 60.68; H, 3.18; N,
11.06. Found: C, 60.66; H, 3.21; N, 11.18. IR (KBr, cm1):
3625 (OH), 3316, 3205 (2NH), 3064 (CH aromatic), 2213
(CN), 1672 (C‚O quinazolinone). 1H NMR (DMSO-d6, d,
ppm): 7.56–8.27 (m, 17H, aromatic protons including 1 H of
pyridine), 10.75 (s, 1H, HN), 11.32 (s, 1H, NH‚C), 11.52 (s,
1H, OH). MS (m/z): 633 (M+, 0.3%), 467 (100%), 351
(0.37%), 103 (27.01%), 75 (93.08%), 50 (28.30%).
5.1.8.4. 2-Imino-6-(4-(6-iodo-4-oxo-2-phenylquinazolin-3(4H)-
yl)phenyl)-4-(4-methylphenyl)-1,2-dihydropyridine-3-carboni-
trile (11d). Yield, 72%; m.p.: 320–2 C. Analysis for
C33H22IN5O (m. w. 631); Calcd.: C, 62.77; H, 3.51; N, 11.09.
Found: C, 62.30; H, 3.28; N, 11.42. IR (KBr, cm1): 3333
(2NH overlapped), 3035 (CH aromatic), 2220 (CN), 1673
(C‚O quinazolinone). 1H NMR (DMSO-d6, d, ppm): 2.54
(s, 3H, CH3), 7.53–8.20 (m, 17H, aromatic protons including
1 H of pyridine), 10.83 (s, 1H, HN), 11.31 (s, 1H, NH‚C).
5.1.9. 2-Amino-6-(4-(6-iodo-4-oxo-2-phenylquinazolin-3(4H)-yl)
phenyl)-4-substituted-4H-pyran-3-carbonitrile (12a–b)
General method:
A mixture of ketone (4) (0.93 g, 0.002 mol), malononitrile
(0.12 ml, 0.002 mol) and the appropriate aromatic aldehyde
(0.002 mol) with few drops of piperidine in 10 ml of n-
butanol was reﬂuxed for 4 h. The reaction mixture was concen-
trated to half of its volume under reduced pressure. After cool-
ing, the formed precipitate was ﬁltered, washed with cold
water, air dried and crystallized from ethanol to give the cor-
responding compounds (12a–b) respectively.
5.1.9.1. 2-Amino-4-(4-chlorophenyl)-6-(4-(6-iodo-4-oxo-2-phenyl-
quinazolin-3(4H)-yl)phenyl)-4H-pyran-3-carbonitrile (12a).
Yield, 81%; m.p.: 210–2 C. Analysis for C32H20ClIN4O2
(m. w. 655); Calcd.: C, 58.69; H, 3.08; N, 8.56. Found: C,
58.73; H, 3.14; N, 8.66. IR (KBr, cm1): 3298 (NH2), 3089
(CH aromatic), 2194 (CN), 1664 (C‚O of quinazolinone).MS (m/z): 655 (M+, 17.69%), 350 (19.90%), 139 (17.98%),
105 (52.63%), 77 (100%), 55 (64.81%).
5.1.9.2. 2-Amino-4-(4-hydroxyphenyl)-6-(4-(6-iodo-4-oxo-2-
phenylquinazolin-3(4H)-yl)-phenyl)-4H-pyran-3-carbonitrile
(12b). Yield, 78%; m.p.: 201–3 C. Analysis for C32H21IN4O3
(m. w. 636); Calcd.: C, 60.39; H, 3.33; N, 8.80. Found: C,
60.37; H, 3.38; N, 8.87. IR (KBr, cm1): 3618 (OH), 3302
(NH2), 3075 (CH aromatic), 2189 (CN), 1666 (C‚O of quina-
zolinone). 1H NMR (DMSO-d6, d, ppm): 1.91 (d, 1H, CH of
pyran), 2.55 (d, 1H, CH of pyran), 7.53–8.19 (m, 16H, aro-
matic protons), 10.83 (s, 2H, NH2), 11.31 (s, 1H, OH). MS
(m/z): 634 (M2, 4.68%), 351 (14.10%), 135 (18.66%), 105
(35.46%), 77 (86.29%), 63 (19.53%), 51 (100%).
5.2. Docking studies
In the present work, all the target compounds were subjected
to docking study to explore their binding mode to GABA-A
receptor. All modeling experiments were performed using mol-
soft (ICM-Pro) program which provides a unique set of tools
for the modeling of protein/ligand interactions. It predicts
how small ﬂexible molecules such as substrates or drug candi-
dates bind to a protein of known 3D structure represented by
grid interaction potentials (ﬁle:///E:/molsoft%20from%
20net-/molsoft%20from%20net/icm_pro.html). Each experi-
ment used the biological target GABA-A receptor downloaded
from the Brookhaven Protein Databank (www. rcsb. Org PDB
ID 4COF). In order to qualify the docking results in terms of
accuracy of the predicted binding conformations in compar-
ison with the experimental procedure, the reported GABA-A
receptor stimulant drug (Methaqualone) was used as a refer-
ence ligand. The docking study has been conducted to predict
the binding mode and to rationalize the observed biological
activity.
5.3. Anticonvulsant evaluation
The animal studies were undertaken with approval from the
Ethics Committee (approval#23PD/3/12/8R) of Al-Azhar
University, Nasr City, Cairo, Egypt. All the trials were carried
out according to the respective internationally guidelines.
Swiss albino adult male mice, weighing 20–25 g, were used as
experimental animals. They were obtained from an animal
facility (Animal house, Department of Pharmacology and
Toxicology, Faculty of Pharmacy, Al-Azhar University).
Mice were housed in stainless steel wire-ﬂoored cages without
any stressful stimuli. Animals were kept under well-ventilated
conditions at room temperature (25–30 C). They were fed
on an adequate standard laboratory chow (El-Nasr Co.,
Abou-Zabal, Egypt) and allowed to acclimatize with free
access to food and water for 24 h period before testing except
during the short time they were removed from the cages for
testing. Albino mice were randomly arranged in groups, each
of six animals. Methaqualone and phenobarbital sodium
(Sigma–Aldrich Chemical Co, Milwaukee, WI, USA) were
used as reference drugs for comparison. The newly synthesized
compounds were screened to evaluate their anticonvulsant
activity and their neurotoxicity. The anticonvulsant activities
of the selected compounds were evaluated by two models,
pentylenetetrazole (PTZ), and maximal electroshock (MES)
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Aldrich Chemical Co, Milwaukee, WI, USA) was used to
induce convulsions in the experimental animals. The test com-
pounds and methaqualone were dissolved in 10% DMSO and
injected intraperitoneally (i.p.) at a dose ranging from 150 to
50 mg/kg animal weight using the same dosing volume of
0.2 ml per 20 g. PTZ (PTZ, Sigma) was dissolved in normal
saline in 2% concentration and was given (i.p.) in a dose of
60 mg/kg body weight (dose that could induce convulsions in
at least 80% of the animals without death during the following
24 h). Phenobarbital sodium (Sigma, USA) was dissolved in
normal saline in 2% concentration and it was i.p. given in
doses of 6.25, 12.5, and 25 mg/kg using the same dosing vol-
ume. All drugs were freshly prepared to the desired concentra-
tion just before use.
Groups of six mice were administered the graded doses of
the test compounds. Control animals received an equal volume
of saline (10 ml/kg). After 1 h, the animals were subcuta-
neously injected with the convulsive dose of PTZ (60 mg/kg).
The criterion of anticonvulsant activity is complete protection
against convulsions of any kind. Observations were made at
least 60 min after the administration of PTZ. Doses that gave
full protection against the induced convulsions and the ED50
of each compound (in mg/kg and millimole) which exhibited
50% protection in addition to the relative potencies of the test
compounds to phenobarbital sodium and methaqualone were
calculated and used for comparison among compounds under
test as shown in Table 2.
In the MES test, the test compounds and methaqualone
were injected intraperitoneally (i.p.) at a dose of 100 mg/kg
before electrical induction of convulsions with maximal elec-
troshocks (MES). The electrical stimulus produced from elec-
troconvulsiometer was 50 mA, 60 Hz. Current was applied
for 0.2 s via auricular electrodes. Protection against the spread
of MES-induced seizures was identiﬁed by the abolition of the
hind leg and tonic maximal extension component of the
seizure.32
The highest potent compounds 7a, 9a, 9b and 12a were fur-
ther evaluated at different doses in PTZ model to determine
their protective and therapeutic indexes.
Neurotoxicity which was indicated by median toxic dose
producing minimal neurological toxicity in 50% of mice
(TD50) was calculated (in mg/kg) and used for comparison
among compounds under test as shown in Table 3.
Neurological toxicity (NT) was determined by rotarod test
in mice using the method reported by Dunham and Miya.27 In
brief, a group of animals (mice) were trained to balance on a
rotating rod (3 cm diameter and 6 rpm speed) and they were
allowed three attempts to remain on the rotating rod for
20 s. The trained animals were treated with the tested com-
pounds at various dose levels by i.p. administration. The tested
compounds were considered to be neurotoxic at a particular
dose level if the trained animal showed lack of Rolling
Roller Performance. The trained animals were tested in this
manner at 30 min and 4 h after the drug administration and
then the neurotoxic effect was recorded in terms of median
toxic dose (TD50). The protective index was determined from
the equation (PI = TD50/ED50). The median lethal dose
(LD50), the dose that causes 50% mortality in mice was calcu-
lated (in mg/kg) and used for comparison among compounds
under test as shown in Table 3. Therapeutic index was deter-
mined from the equation (TI = LD50/ED50).6. Conﬂict of interest
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